FDA Accepts NDA for Combination Drug to Treat Type 2 Diabetes

Published April 15, 2014

FDA accepts NDA for combination drug to treat type 2 diabetes
The US Food and Drug Administration (FDA) has accepted the filing of the new drug application (NDA) for Boehringer Ingelheim and Eli Lilly's investigational combination tablet of empagliflozin and linagliptin to treat adults with type 2 diabetes (T2D).
Read more on Pharmaceutical Business Review